L

Lexeo Therapeutics Inc
NASDAQ:LXEO

Watchlist Manager
Lexeo Therapeutics Inc
NASDAQ:LXEO
Watchlist
Price: 6.53 USD -0.76%
Market Cap: 215.9m USD
Have any thoughts about
Lexeo Therapeutics Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-1.4
Current
-4.6
Median
4.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.4
=
Enterprise Value
97.4m USD
/
EBITDA
-67.9m USD
All Countries
Close
Market Cap EV/EBITDA
US
Lexeo Therapeutics Inc
NASDAQ:LXEO
217.6m USD -1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -221 216.4
US
Abbvie Inc
NYSE:ABBV
315.9B USD 15.4
US
Amgen Inc
NASDAQ:AMGN
140.9B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
115.5B USD 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD 21.6
US
Epizyme Inc
F:EPE
94.1B EUR -510.8
AU
CSL Ltd
ASX:CSL
135.9B AUD 19.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD 15.5
US
Seagen Inc
F:SGT
39.3B EUR -58.3
NL
argenx SE
XBRU:ARGX
36.1B EUR -156.7
EBITDA Growth EV/EBITDA to Growth
US
L
Lexeo Therapeutics Inc
NASDAQ:LXEO
Average EV/EBITDA: 16.4
Negative Multiple: -1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -221 216.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -510.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
12%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -156.7 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1
2-Years Forward
EV/EBITDA
-1.2
3-Years Forward
EV/EBITDA
-1.2